Peptide Price Index 2026: 90-Day Vendor Trends

Across the trailing 90 days — May 3 to August 1, 2026 — a daily scraper captured 3,596 public price observations covering 56 peptides, 268 distinct SKUs, and 9 anonymized vendors. Normalized to a per-mg basis, the spread between the cheapest and most expensive compounds in the dataset runs from NAD+ at a $0.14/mg median to tesamorelin at $14.00/mg — a 100× range inside a single market.

The headline number for anyone planning a purchase is the aggregate stockout rate: 12.2% of vendor-day observations showed a product unavailable, concentrated heavily in BPC-157 (44.8% OOS) and NAD+ (33.3%). Prices in this market move less than availability does.

Methodology

Research-context information only. This report describes industry pricing patterns observed over a trailing 90-day window. Nothing in this report is medical advice, financial advice, or a recommendation to buy or sell any peptide. Peptides discussed are research compounds; most are not approved by the FDA for human use. Consult a licensed physician for personal medical decisions.

Vendor identities are anonymized to maintain editorial independence. Pricing data is normalized to a per-mg basis. All data sourced from publicly-listed vendor prices captured daily during the data window.

The pipeline is simple. A daily scraper visits each tracked vendor's product pages, parses the listed price and stock status, and writes a snapshot row to an offer_price_history table. Each row is one (vendor, SKU, captured-at) tuple. We do not use cached data, retail aggregators, or rumored prices — every observation is a public price visible to any buyer on the day it was captured.

Per-mg normalization is computed as price_cents ÷ (mg_per_vial × vial_count) so a 10-vial bundle of 5mg vials at $400 normalizes to the same $8.00/mg as a single 10mg vial at $80.

For this report, vendors are renamed Vendor A, Vendor B, Vendor C, … using a stable SHA-1 hash of their internal id. The hash sort means a given vendor keeps the same label across successive monthly refreshes — but you cannot reverse-engineer the label back to the vendor without access to the source database. That is intentional.

Median and range figures below are computed from in-stock observations only; stockout rates are computed from all observations.

Cross-Peptide Trends

The chart above plots a 7-day rolling median per-mg price for the most-tracked peptides over the trailing 90-day window (May 3 – August 1, 2026). Three patterns stand out.

The commodity peptides stayed cheap and stayed put. NAD+ (around $0.14/mg) and GHK-Cu bulk vials (around $0.65/mg) traced essentially flat lines across the full window. These are the compounds sold in 100mg, 500mg, and 1000mg vials, where the per-mg arithmetic collapses the price into commodity territory regardless of what any single vendor does.

The mid-market clustered in a $5–$12 band. BPC-157 ($5.30/mg median), KPV ($5.00), selank ($5.00), epitalon ($5.00), retatrutide ($6.60), sermorelin ($7.20), 5-amino-1MQ ($7.50), SS-31 ($7.50), CJC-1295 ($10.00), ipamorelin ($10.00), TB-500 ($12.00), and AOD-9604 ($12.00) all landed inside it. That band is where most of the market lives, and it moved very little week to week.

Observed medians drifted lower — but the drift is mostly cohort composition, not repricing. All six deep-dive peptides showed a lower median in the last two weeks of the window than in the first two, ranging from -15% (sermorelin) to -31% (NAD+). A like-for-like check undercuts the obvious reading. Holding both vendor and vial size constant, tirzepatide's 10mg tier moved $7.50 → $6.90 while its 30mg tier moved $3.93 → $5.67 in the same window — opposite directions. For BPC-157, NAD+, and sermorelin, the late-window sample narrowed to a single vendor that happened to be the cheaper one in the cohort.

That last point is the most important methodological caveat in this report. Vendor coverage expanded from 6 vendors and 34 peptides in May to 8 vendors and 52 peptides in July. When the set of vendors being captured changes, the median changes with it — no vendor has to touch a price tag. These medians describe what a buyer could see on a given day. They are not a market-wide price index.

Per-Peptide Deep Dives

Each of the six peptides below has its own daily-range chart. The vertical wicks show the min-to-max per-mg price across all vendors on that day; the yellow dots are the daily median. No vendor lines, no vendor labels — this is supply-side dispersion only.

Tirzepatide

• Observations: 364 across 6 vendors (15 distinct SKUs)
• Median per-mg: $5.67
• Range across full window: $1.99 – $219.80 per mg (95th percentile: $6.95)
• Daily-median pricing changes (>0.5%): 24
• OOS rate: 1.4%

Tirzepatide is the most-tracked peptide in the dataset at 364 observations, and it carries the lowest stockout rate of any deep-dive peptide — 1.4%. Supply is deep enough that no shortage pressure is visible anywhere in the window.

The full range looks alarming and mostly isn't. The $219.80/mg top is a single observation of a 5mg trial-size SKU at $1,099; the 95th percentile sits at $6.95/mg, so the median describes essentially all real buying. The genuine structure is vial-size tiering: 10mg vials ran a $6.90 median, 30mg vials $3.97, and the one 100mg SKU in the cohort priced at $1.99/mg. Per-mg cost falls roughly 3× from the smallest common vial to the largest.

For ranked vendor options, see Best Tirzepatide Vendors.

Tirzepatide is the active ingredient in approved finished pharmaceutical products. The pricing in this dataset is for research-chemical compounded forms, which are not FDA-approved.

Retatrutide

• Observations: 109 across 5 vendors (17 distinct SKUs)
• Median per-mg: $6.60
• Range across full window: $3.08 – $12.50 per mg (95th percentile: $10.00)
• Daily-median pricing changes (>0.5%): 33
• OOS rate: 12.8%

Retatrutide has the noisiest daily median in the deep-dive set — 33 daily-median moves greater than 0.5%, across only 60 day-to-day transitions with enough in-stock data to compare. That is a mechanical effect more than a market one: five vendors carrying 17 SKUs means any single vendor going in or out of stock swings the median measurably.

The absolute range is contained by comparison — $3.08 to $12.50/mg, roughly 4×, with no extreme outliers. Vial sizes ran from 5mg to 48mg, and the 12.8% stockout rate is the third-highest in the deep-dive group. Retatrutide remains an investigational molecule and supply is visibly thinner than tirzepatide's.

For ranked vendor options, see Best Retatrutide Vendors.

Retatrutide is investigational and not FDA-approved. All pricing is for research-grade material.

BPC-157

• Observations: 210 across 4 vendors (8 distinct SKUs)
• Median per-mg: $5.30
• Range across full window: $2.87 – $79.98 per mg (95th percentile: $74.00)
• Daily-median pricing changes (>0.5%): 13
• OOS rate: 44.8%

BPC-157 carries the highest stockout rate in the entire dataset — 44.8% of its vendor-day observations showed the product unavailable, close to one in two. Ongoing regulatory pressure around BPC-157 coincides with that inventory strain, though this dataset records availability, not cause.

The price structure is genuinely two-tiered rather than outlier-driven. Bulk vials (10mg, 20mg, 30mg) ran $2.87–$7.00/mg with a $5.30 median. The 5mg tier split: 91 observations at $11.00/mg and nine at $74.00–$79.98/mg from a single premium retail source. That premium tier is 4.3% of all BPC-157 observations — small, but large enough that the 95th percentile lands at $74.00 rather than in the bulk range. Just over half of all observations (52.4%) priced at or below $10.00/mg.

For ranked vendor options, see Best BPC-157 Vendors.

NAD+

• Observations: 132 across 4 vendors (7 distinct SKUs)
• Median per-mg: $0.14
• In-stock range: $0.09 – $0.18 per mg (full-window max $25.00 — a single 1mg SKU)
• Daily-median pricing changes (>0.5%): 10
• OOS rate: 33.3%

NAD+ is the cheapest compound in the dataset by two orders of magnitude, and the reason is vial size: 1000mg vials accounted for 93 of its 132 observations. At that scale the per-mg cost lands in commodity territory — a $0.09 to $0.18 band that barely moved all window, with only 10 daily-median changes above 0.5%.

The $25.00/mg figure in the raw data is one observation of a 1mg SKU that was out of stock at capture. It is the sole reason NAD+ tops the volatility leaderboard below, and it is not a price any buyer transacted at during the window.

Availability is the real story. The 500mg tier was out of stock in 91.9% of its observations while the 1000mg tier sat at 9.7% — a 33.3% blended rate driven almost entirely by one vial size being persistently dark.

Sermorelin

• Observations: 96 across 4 vendors (4 distinct SKUs)
• Median per-mg: $7.20
• Range across full window: $6.30 – $10.00 per mg (95th percentile: $8.50)
• Daily-median pricing changes (>0.5%): 8
• OOS rate: 5.2%

Sermorelin is the most stably priced peptide in the deep-dive set on every measure: the tightest range ($6.30–$10.00/mg, a 1.6× spread), the fewest daily-median changes (8), a 9.8% coefficient of variation, and a low 5.2% stockout rate. Every observation in the window came from a 10mg vial, so none of that tightness is an artifact of SKU uniformity being mistaken for price agreement — the vendors genuinely price sermorelin within a narrow band.

That pattern is consistent with a mature compound: a long history as a GHRH analog, an established compounded-pharmacy channel, and no supply events during the window.

GHK-Cu

• Observations: 130 across 5 vendors (10 distinct SKUs)
• Median per-mg: $0.79
• Range across full window: $0.45 – $59.95 per mg
• Daily-median pricing changes (>0.5%): 25
• OOS rate: 15.4%

GHK-Cu is the clearest example in the dataset of a compound where a single median hides the market. It splits into two genuinely separate segments rather than a core plus outliers.

The bulk segment — 50mg and 100mg vials, 82% of observations — ran a $0.65/mg median across a $0.45–$13.79 range. The small-vial segment — 1mg and 2mg SKUs, 16.2% of observations — priced at $34.95–$59.95/mg. These are not the same purchase. Small-vial GHK-Cu at those per-mg prices generally reflects cosmetic and topical formulations, where the buyer is paying for the finished product rather than the raw peptide mass.

Quoting a blended $0.79/mg median for GHK-Cu is technically correct and practically misleading. The segment number is the one that matters.

Volatility Leaderboard

The chart plots the coefficient of variation (CoV) of per-mg pricing for every peptide with at least 30 observations in the trailing-90-day window — 27 peptides qualified. CoV = standard deviation ÷ mean, expressed as a percent. Higher = wider spread between vendors, SKUs, and time.

Reading the leaderboard:

• Above 60% CoV: NAD+ (683%), GHK-Cu (203%), tirzepatide (186%), BPC-157 (128%), TB-500 (80%). Every one of these is driven by SKU-mix dispersion, not vendor disagreement. NAD+'s 683% comes from a single 1mg observation sitting alongside 1000mg vials; GHK-Cu's from the cosmetic-vs-bulk split; tirzepatide's from one trial-size SKU; BPC-157's and TB-500's from premium 5mg retail pricing alongside bulk vials. Comparing like vial sizes inside these compounds produces far tighter numbers.
• 30–60% CoV: 5-amino-1MQ (30.5%), semax (30.4%). Genuine mid-range dispersion across a modest vendor pool.
• 15–30% CoV: retatrutide (29.8%), KPV (26.1%), tesamorelin (24.5%), pinealon (23.2%), MOTS-c (21.2%), epitalon (20.5%), CJC-1295 (17.3%). The comparison-shopping zone — real spread between vendors on the same product.
• Below 15% CoV: melanotan-1 (14.4%), SS-31 (14.2%), DSIP (14.1%), cagrilintide (14.1%), AOD-9604 (13.4%), thymosin alpha-1 (12.2%), selank (11.0%), melanotan-2 (10.2%), sermorelin (9.8%), kisspeptin (9.2%), ipamorelin (8.4%), PT-141 (7.3%), cartalax (6.3%). Thirteen of the 27 tracked peptides — nearly half the market — price within a tight band across every vendor in the cohort.

The practical read: a high CoV number on this chart is a prompt to check what SKU sizes are being compared, not automatically a signal that one vendor is overcharging. Where a compound shows both high CoV and uniform vial sizes — retatrutide and KPV are the cleanest examples — the dispersion is vendor pricing rather than packaging.

Supply Patterns

The heatmap above shows OOS rate per peptide per ISO week. Darker = more vendor-days marked out of stock during that week.

Aggregate stockout rate for the window: 12.2%, meaning roughly one in eight vendor-day observations across the dataset showed a product as unavailable.

The weekly trend improved materially through the window. Availability was worst in early May — the week of May 4 peaked at 25.6% OOS — then declined nearly monotonically to a 4.8% low in the week of June 29. A second spike hit 19.2% in the week of July 6 before settling back to 5–9% through late July. The window ends in better supply condition than it started.

Concentration matters more than the aggregate. The peptides carrying sustained dark bands are BPC-157 (44.8% OOS), pinealon (43.5%), NAD+ (33.3%), and tesamorelin (32.0%). Below those four, the drop is steep: GHK-Cu at 15.4%, retatrutide at 12.8%, SS-31 at 12.1%, and everything else in single digits. The dataset's 12.2% aggregate is not a market-wide scarcity signal — it is four compounds under real pressure and a long tail that is broadly well-stocked.

Stockout patterns also interact with price. When one or two vendors go dark, the median per-mg price visible to buyers can drift upward simply because the cheapest vendor disappeared from the cohort — the same composition effect described in the cross-peptide section. The price chart and the OOS chart are best read together.

What This Means for Buyers

Generic, evergreen guidance based on the patterns visible across the window:

Check vial size before concluding a vendor is expensive. This is the single largest source of apparent price difference in the dataset. Tirzepatide's per-mg cost fell roughly 3× from its 10mg tier to its 100mg tier. NAD+'s entire 100× advantage over mid-market peptides is vial-size arithmetic. Four of the five highest-volatility compounds on the leaderboard are high-volatility only because their SKU mix is heterogeneous.

Comparison shopping pays on some compounds and not others. Retatrutide, KPV, tesamorelin, MOTS-c, epitalon, and CJC-1295 showed 17–30% CoV with comparable SKUs — genuine vendor-to-vendor spread. Sermorelin, PT-141, ipamorelin, kisspeptin, and melanotan-2 all sat under 11%, where the delta between vendors is smaller than the difference shipping speed or COA documentation makes.

Availability is the binding constraint, not price. With BPC-157 at 44.8% and NAD+ at 33.3% OOS, a buyer's practical problem on those two compounds is finding stock rather than finding a good price. The weekly heatmap shows those bands persisting across multiple consecutive weeks, not resolving in days.

Per-mg, not per-vial. Vial sizes in this dataset ranged from 1mg to 1000mg. Comparing dollar prices without normalizing to per-mg is the largest avoidable source of overpaying in this market.

Premium small-vial SKUs distort every summary statistic. When a peptide shows a max per-mg price 5–10× its median, it is almost always a 1mg, 2mg, or 5mg trial-size or cosmetic SKU at full retail. GHK-Cu's small-vial segment prices 50× above its bulk segment for what is nominally the same compound.

End-of-month vs. mid-month. This window was not granular enough to confirm end-of-month promotional pricing as a reliable pattern. Some vendors run periodic clearance events; others price flat. Future refreshes will track this more carefully.

If you want a vendor starting point without doing your own daily price tracking, our Best Peptide Vendors of 2026 compares the top-rated vendors on price, COA documentation, shipping reliability, and reputation. That ranking is updated continuously as data shifts.

Methodology Limitations

In the spirit of editorial independence, the limitations of this dataset:

1. The window covers May 3 – August 1, 2026 (trailing 90 days), with data captured on 91 of those days. Each monthly refresh rolls this window forward, so the figures always describe the most recent quarter of live prices rather than a fixed calendar quarter.
2. Cohort composition changed materially during the window. Coverage grew from 6 vendors and 34 peptides in May to 8 vendors and 52 peptides in July, while one vendor tapered out of the dataset entirely. Period-over-period median comparisons are therefore unreliable in this edition, and the report avoids making them. This is the largest limitation in the current dataset.
3. Per-mg normalization assumes purity parity. It does not hold. Two vendors selling 10mg of "BPC-157" may ship different actual peptide quantities depending on assay results. This dataset takes the listed mg figure at face value and does not adjust for COA-reported purity.
4. Bundle SKUs were normalized as mg_per_vial × vial_count. This is the right adjustment for buyers comparing per-mg cost, but it slightly compresses the apparent vendor-spread for peptides where bundle pricing varies significantly per-vial.
5. Cosmetic and topical formulations are priced alongside research-grade vials. GHK-Cu is the clearest case — its 1mg and 2mg SKUs are finished topical products, not raw peptide, but they normalize into the same per-mg column. This inflates both the range and the CoV for any compound sold in both formats.
6. Nine vendors is a meaningful slice but not exhaustive. The cohort skews toward English-language US-shipping research-grade vendors. Non-US vendors and prescription-only compounded sources are not in this dataset.
7. Anonymization is an editorial choice, not a privacy requirement. All prices in this dataset were public on vendor websites at the time of capture. We anonymize because it lets us report on industry-wide patterns without our affiliate relationships influencing the analysis.
8. The OOS flag reflects what the vendor's website displayed. Some vendors mark a SKU as "available — backorder 7 days," which we treat as in-stock; others show "out of stock" the moment inventory hits zero. Inter-vendor stock-status reporting is not strictly comparable.

Coming Next

This report refreshes monthly, with each version covering a rolling trailing-90-day window on full daily scraper cadence. The chart set and anonymization scheme stay constant across refreshes so successive versions are directly comparable.

Planned additions to future refreshes:

• Vial-size-normalized medians — per-mg figures computed within matched SKU tiers, so headline numbers stop moving when the SKU mix changes
• Period-over-period delta for every peptide with a stable vendor cohort across successive windows
• End-of-month vs. mid-month pricing pattern test
• Stockout-to-price-recovery lag — how many days between OOS-onset and post-restock pricing returning to baseline

Where to buy if you're researching options

For most readers landing here from FDA / vendor / pricing coverage, the two highest-utility next-stops on this site are:

• Retatrutide Buying Guide — vendor pricing, COA verification, vial-size tradeoffs for the highest-search-volume peptide of 2026
• Best Peptide Vendors of 2026 — head-to-head vendor comparison ranked by price, COA documentation, and reputation